Keros Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4923271013
USD
10.69
-0.46 (-4.13%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Ligand Pharmaceuticals, Inc.
ImmunityBio, Inc.
Keros Therapeutics, Inc.
Revance Therapeutics, Inc.
Day One Biopharmaceuticals, Inc.
MannKind Corp.
Viking Therapeutics, Inc.
Morphic Holding, Inc.
89bio, Inc.
ACELYRIN, Inc.
EQRx, Inc.

Why is Keros Therapeutics, Inc. ?

1
Negative results in Jun 26
  • NET SALES(HY) At USD 0.37 MM has Grown at -99.84%
  • NET PROFIT(HY) At USD -52.42 MM has Grown at -144.51%
  • RAW MATERIAL COST(Y) Grown by 101.03% (YoY)
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -16.54%, its profits have risen by 146.5% ; the PEG ratio of the company is 0
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -16.54% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Keros Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Keros Therapeutics, Inc.
-22.14%
-1.51
51.01%
S&P 500
21.34%
1.69
13.20%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
200.51%
EBIT Growth (5y)
28.10%
EBIT to Interest (avg)
-81.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.18
Tax Ratio
71.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0.14%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
5
Industry P/E
Price to Book Value
1.43
EV to EBIT
2.19
EV to EBITDA
2.15
EV to Capital Employed
8.18
EV to Sales
0.61
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
373.25%
ROE (Latest)
28.73%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
NO KEY POSITIVE TRIGGERS
-18What is not working for the Company
NET SALES(HY)

At USD 0.37 MM has Grown at -99.84%

NET PROFIT(HY)

At USD -52.42 MM has Grown at -144.51%

RAW MATERIAL COST(Y)

Grown by 101.03% (YoY

EPS(Q)

Lowest at USD -1.45

Here's what is not working for Keros Therapeutics, Inc.

Net Sales
At USD 0.37 MM has Grown at -99.84%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Net Profit
At USD -52.42 MM has Grown at -144.51%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

EPS
Lowest at USD -1.45
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost
Grown by 101.03% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales